Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CLDN18.2-targeted antibody-drug conjugate
DRUG CLASS:
CLDN18.2-targeted antibody-drug conjugate
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
EO-3021 (5)
SOT102 (5)
AZD0901 (4)
BMS-986476 (3)
ATG-022 (1)
IBI-343 (1)
RC118 (0)
SHR-A1904 (0)
SKB315 (0)
TQB2103 (0)
EO-3021 (5)
SOT102 (5)
AZD0901 (4)
BMS-986476 (3)
ATG-022 (1)
IBI-343 (1)
RC118 (0)
SHR-A1904 (0)
SKB315 (0)
TQB2103 (0)
›
Associations
(23)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
AZD0901
Sensitive: B - Late Trials
AZD0901
Sensitive
:
B
AZD0901
Sensitive: B - Late Trials
AZD0901
Sensitive
:
B
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
AZD0901
Sensitive: B - Late Trials
AZD0901
Sensitive
:
B
AZD0901
Sensitive: B - Late Trials
AZD0901
Sensitive
:
B
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
EO-3021
Sensitive: B - Late Trials
EO-3021
Sensitive
:
B
EO-3021
Sensitive: B - Late Trials
EO-3021
Sensitive
:
B
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
IBI-343
Sensitive: B - Late Trials
IBI-343
Sensitive
:
B
IBI-343
Sensitive: B - Late Trials
IBI-343
Sensitive
:
B
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
EO-3021
Sensitive: B - Late Trials
EO-3021
Sensitive
:
B
EO-3021
Sensitive: B - Late Trials
EO-3021
Sensitive
:
B
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AZD0901
Sensitive: C2 – Inclusion Criteria
AZD0901
Sensitive
:
C2
AZD0901
Sensitive: C2 – Inclusion Criteria
AZD0901
Sensitive
:
C2
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AZD0901
Sensitive: C2 – Inclusion Criteria
AZD0901
Sensitive
:
C2
AZD0901
Sensitive: C2 – Inclusion Criteria
AZD0901
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Solid Tumor
CLDN18.2 expression
Solid Tumor
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Lung Cancer
CLDN18.2 expression
Lung Cancer
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18-ARHGAP fusion
Gastric Cancer
CLDN18-ARHGAP fusion
Gastric Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: C3 – Early Trials
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
C3
CLDN18.2-targeted antibody-drug conjugate
Sensitive: C3 – Early Trials
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
C3
CLDN18.2 positive
Pancreatic Cancer
CLDN18.2 positive
Pancreatic Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2 underexpression
Gastric Cancer
CLDN18.2 underexpression
Gastric Cancer
ATG-022
Sensitive: D – Preclinical
ATG-022
Sensitive
:
D
ATG-022
Sensitive: D – Preclinical
ATG-022
Sensitive
:
D
CLDN18.2 underexpression
Pancreatic Cancer
CLDN18.2 underexpression
Pancreatic Cancer
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
CLDN18.2 overexpression
Pancreatic Cancer
CLDN18.2 overexpression
Pancreatic Cancer
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
CLDN18.2 overexpression
Gastric Cancer
CLDN18.2 overexpression
Gastric Cancer
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
BMS-986476
Sensitive: D – Preclinical
BMS-986476
Sensitive
:
D
CLDN18.2 expression
Lung Adenocarcinoma
CLDN18.2 expression
Lung Adenocarcinoma
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Colon Cancer
CLDN18.2 expression
Colon Cancer
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Hepatocellular Cancer
CLDN18.2 expression
Hepatocellular Cancer
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Endometrial Cancer
CLDN18.2 expression
Endometrial Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2 expression
Ovarian Cancer
CLDN18.2 expression
Ovarian Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login